dr. charles ryan discusses abiraterone and enzalutamide for mcrpc
Published 10 years ago • 469 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
0:56
dr. charles j. ryan on patients with mcrpc treated with abiraterone
-
1:22
dr. charles ryan discusses neoadjuvant abiraterone acetate
-
1:12
dr. charles ryan discusses imaagen trial update for prostate cancer
-
1:12
dr. pal on sequencing abiraterone and enzalutamide in mcrpc
-
1:14
charles ryan, md: the role of abiraterone plus prednisone in patients with diabetes
-
2:10
charles ryan, md: the differences in side effects between the two ar-targeted therapies
-
2:26
charles ryan, md: the efficacy of abiraterone plus prednisone in an elderly patient population
-
18:58
intermediate risk prostate cancer
-
4:01
understanding advanced prostate cancer
-
22:55
recurrent prostate cancer cases panel
-
1:23
dr. charles ryan abiraterone acetate in elderly mcrpc patients
-
1:16
dr. charles ryan on the cou-aa-302 abiraterone acetate interim analysis results
-
2:06
dr. charles ryan discusses sequencing prechemotherapy castration-resistant prostate cancer therapies
-
0:54
dr. ryan on the long term safety of abiraterone use
-
1:49
dr. ryan on bone-targeting agents for patients with prostate cancer
-
1:35
charles ryan, md: the side effects for prednisone in combination with abiraterone
-
1:05:07
january 8, 2019 - charles ryan, md
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
2:06
the role of abiraterone in prostate cancer
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
3:02
charles ryan, md: treatment options and favorable approaches for an elderly patient
-
8:12
the use of abiraterone and enzalutamide against crpc